MedTrace Logo

Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

NCT04405167 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-10-07

No results posted yet for this study

Summary

This study is the first study of tasquinimod, an inhibitor of S100A9, in patients with multiple myeloma.

Conditions

Interventions

DRUG

Tasquinimod

Tasquinimod will be supplied as oral capsules.

DRUG

IRd chemotherapy

IRd chemotherapy with ixazomib, lenalidomide, and dexamethasone

Sponsors & Collaborators

Principal Investigators

  • Dan Vogl, MD · University of Pennsylvania

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-10
Primary Completion
2025-05-19
Completion
2025-07-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04405167 on ClinicalTrials.gov